NextGen NeuroCORE GlioSeq
Neurocore GlioSeq Gene Panel by NGS, FFPE Tissue** Price
Brief Details
What is a NextGen NeuroCORE GlioSeq?
The NextGen NeuroCORE GlioSeq is a specialised genetic test that uses Next Generation Sequencing (NGS) technology to examine brain tumour tissue. This advanced molecular test creates a detailed genetic profile of gliomas and other central nervous system tumours by analysing their DNA for specific mutations, alterations, and fusions.
The test helps doctors accurately classify brain tumour types, predict how aggressive they might be, and identify the most suitable targeted treatments for each patient.
What Does the NextGen NeuroCORE GlioSeq Measure?
This comprehensive NGS sequencing test measures several key molecular features of brain tumours:
- Gene mutations - Identifies changes in key genes like IDH1, IDH2, TP53, ATRX, and TERT promoter that are crucial for tumour classification.
- Gene fusions - Detects when parts of different genes join together, such as BRAF or FGFR3 fusions that can be targeted with specific treatments.
- Copy number variations - Checks for extra or missing copies of genes, like EGFR amplification commonly found in aggressive glioblastoma.
- Chromosomal alterations - Identifies changes in chromosome structure, including 1p/19q co-deletion.
- Treatment response biomarkers - Identifies genetic markers that predict how your tumour might respond to chemotherapy, targeted therapy, or immunotherapy.
NextGen NeuroCORE GlioSeq: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen NeuroCORE GlioSeq?
This test is not ordered based on symptoms alone but after a brain tumour is suspected or confirmed. Initial symptoms that may lead doctors to investigate for brain tumours include:
- Persistent or worsening headaches, often worse in the morning
- Seizures or fits
- Unexplained nausea and vomiting
- Vision problems such as blurred or double vision
- Gradual loss of sensation or movement in arms or legs
- Difficulty with balance or walking
- Changes in speech, personality, or memory
Who should get a NextGen NeuroCORE GlioSeq?
This specialised test is specifically designed for patients who have already been diagnosed with brain tumours. The target groups include:
- Patients diagnosed with gliomas requiring precise molecular classification.
- Individuals needing prognostic information about their brain tumour.
- Patients whose treatment plans require personalised therapy guidance.
- Those participating in clinical trials based on specific genetic profiles.
- Patients with central nervous system tumours requiring targeted therapy selection.
Why is a NextGen NeuroCORE GlioSeq done?
The test is performed to move beyond traditional one-size-fits-all approaches to brain tumour treatment. It provides critical genetic information that helps doctors choose the most effective therapies and predict patient outcomes with greater accuracy.
Importance of a NextGen NeuroCORE GlioSeq
The NextGen NeuroCORE GlioSeq test represents a breakthrough in personalised neuro oncology care. It provides accurate molecular diagnosis by identifying genetic features that may not be visible under traditional microscopic examination. Two gliomas that appear identical can have completely different genetic profiles, leading to different treatment approaches and outcomes.
This test offers crucial prognostic information, helping doctors and families understand the likely course of the disease and survival expectations. Most importantly, it guides treatment decisions by identifying specific genetic targets for therapy, such as BRAF mutations that may respond to targeted inhibitors, or MGMT promoter methylation that suggests better response to chemotherapy. The test also helps identify patients eligible for clinical trials based on their tumour's unique genetic signature.
NextGen NeuroCORE GlioSeq Booking & Reports – Metropolis Healthcare India
How to Book a NextGen NeuroCORE GlioSeq?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the NextGen NeuroCORE GlioSeq, choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is home sample collection for NextGen NeuroCORE GlioSeq available near you?
No, Metropolis Healthcare does not provide home sample collection for NextGen NeuroCORE GlioSeq Test. This specialised test requires tumour tissue samples that are collected during surgical procedures like biopsy or tumour removal, performed in hospital settings by neurosurgeons. The tissue sample is sent to our NABL & CAP accredited pathology lab, where our expert pathologists and technicians process your sample.
How long does it take to get a NextGen NeuroCORE GlioSeq Report?
Reports are usually available after 4 weeks once the sample reaches the lab.
Note: Reporting time may vary depending on your location.
Where can I see or get NextGen NeuroCORE GlioSeq results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen NeuroCORE GlioSeq Results
What Your NextGen NeuroCORE GlioSeq Results May Indicate
Your NextGen NeuroCORE GlioSeq results provide detailed genetic information about your brain tumour that helps guide treatment decisions:
|
Parameters |
Result Type |
Clinical Significance |
|
IDH1/IDH2 mutations |
Positive/Negative |
Positive results indicate better prognosis and potential response to IDH inhibitors |
|
ATRX mutations |
Positive/Negative |
Found in IDH-mutant astrocytomas, helps classify tumour type |
|
CDKN2A alterations |
Loss/Normal |
Loss indicates higher grade tumours with more aggressive behaviour |
|
1p/19q co-deletion |
Present/Absent |
Present in oligodendrogliomas, associated with better treatment response |
|
Gene fusions (NTRK, FGFR) |
Detected/Not detected |
When detected, specific targeted therapies may be available |
|
Copy number alterations |
Various patterns |
Multiple alterations often indicate higher grade, more aggressive tumours |
Conditions that May Affect NextGen NeuroCORE GlioSeq Accuracy
Several factors can influence the accuracy and interpretation of your NextGen NeuroCORE GlioSeq results:
- Tissue quality and fixation - Improper tissue handling or inadequate fixation can affect DNA quality and test reliability.
- Tumour cell percentage - Low tumour cell content in the sample may reduce sensitivity for detecting genetic alterations.
- Sample heterogeneity - Brain tumours can have different genetic profiles in different areas, potentially affecting results.
- Technical factors - Insufficient DNA quantity or degraded samples may limit the ability to detect certain mutations.
- Timing of sample collection - Samples collected after extensive treatment may show altered genetic profiles.
- Laboratory processing conditions - Temperature variations during transport or storage can impact sample integrity.
How is a NextGen NeuroCORE GlioSeq Done?
The NextGen NeuroCORE GlioSeq follows a systematic process to analyse your tumour's genetic profile:
- Tissue collection - Tumour tissue is obtained during neurosurgical biopsy or tumour removal procedure.
- Sample preparation - Tissue is processed into paraffin-embedded blocks and sectioned onto slides.
- Microscopic review - A pathologist examines stained slides to identify tumour areas for analysis.
- DNA and RNA extraction - Genetic material is carefully isolated from the selected tumour tissue.
- Library preparation - DNA and RNA are prepared for sequencing using specialised molecular techniques.
- Next Generation Sequencing - Advanced sequencing technology analyses multiple genes simultaneously.
- Data analysis - Sophisticated software processes sequencing data to identify genetic alterations.
- Report generation - Expert pathologists interpret results and prepare comprehensive molecular report.
How Should You Prepare for a NextGen NeuroCORE GlioSeq?
Since this test is performed on tissue obtained during surgery, preparation involves following your surgical team's instructions:
- Follow pre-surgical instructions - Your neurosurgeon will provide specific guidelines for the biopsy or tumour removal procedure.
- Medication review - Inform your doctor about all medications, especially blood thinners that may need to be stopped before surgery.
- Medical history - Provide complete clinical history and previous imaging reports to your healthcare team.
- No special dietary restrictions - The laboratory test itself does not require fasting or dietary modifications.
- Consent process - Understand both the surgical procedure risks and the genetic testing implications through informed consent.
Diseases that a NextGen NeuroCORE GlioSeq Can Help Detect
This comprehensive molecular test assists in diagnosing and classifying various central nervous system tumours:
- Glioblastoma - The most aggressive form of brain cancer with specific genetic signatures.
- Astrocytoma - A type of glioma with distinct molecular subtypes based on genetic alterations.
- Oligodendroglioma - Brain tumours characterised by specific genetic markers like 1p/19q co-deletion.
- Ependymoma - Tumours arising from brain lining cells with unique molecular classifications.
- Medulloblastoma - Paediatric brain tumours with distinct genetic classifications.
- Meningioma - Tumours of brain coverings with specific genetic risk factors.
- Atypical teratoid/rhabdoid tumour - Rare aggressive brain tumours with characteristic genetic alterations.
NextGen NeuroCORE GlioSeq/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive cancer screening packages that complement brain tumour diagnosis and monitoring:
|
Test/Package Name |
Purpose/Highlights |
|
Comprehensive screening for brain and pituitary gland tumours |
|
|
Specialised testing for neuroendocrine tumours affecting the nervous system |
|
|
Glioma Panel (1P/19Q, IDH1/2, MGMT) |
Focused genetic testing for key glioma biomarkers and treatment guidance |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.